Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Option exercise Director acquired 3,253 shares (option exercise)
  2. 4 Option exercise Director acquired 3,253 shares (option exercise)
  3. 4 Option exercise Director acquired 3,253 shares (option exercise)
  4. 4 Option exercise Director acquired 3,253 shares (option exercise)
  5. 4 Open-market sale President and CEO sold 18,333 shares at an average $61.40 ($1,125,648)
  6. 4 Open-market sale Director sold 1,666 shares at an average $65.37 ($108,911)
  7. 4 Open-market sale Director sold 46,763 shares at an average $60.11 ($2,811,048)
  8. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $55.49 ($554,864)
  9. 4 Open-market sale Director sold 3,237 shares at an average $60.11 ($194,589)
  10. 4 Open-market sale President and CEO sold 18,333 shares at an average $58.64 ($1,075,102)
  11. 10-Q Report Quarterly Report
  12. 8-K Event Results of operations
  13. 4 Open-market sale Director sold 1,666 shares at an average $62.15 ($103,538)
  14. DEFA14A Proxy Proxy Materials
  15. DEF 14A Proxy Proxy Statement
  16. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $56.09 ($560,901)
  17. 4 Open-market sale Director sold 50,000 shares at an average $56.62 ($2,831,071)
  18. 4 Open-market sale President and CEO sold 18,334 shares at an average $56.60 ($1,037,684)
  19. 4 Open-market sale Director sold 1,666 shares at an average $56.42 ($93,992)
  20. 4 Open-market sale Chief Medical Officer sold 2,822 shares at $54.62 ($154,126)

Page 24 of 40 · 789 filings